Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06670053 · ClinicalTrials.gov registry record
Puberty, Testosterone, and Brain Development
A clinical trial of Headache and Transgender, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06670053: Recruiting study of Headache and Transgender, sponsored by University of Colorado, Denver.
NCT06670053 is a study of Headache and Transgender that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 100 participants, below the 153-participant average among 35 other Headache trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06670053, a study of Headache and Transgender, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Transmasculine youth (female sex assigned at birth, male gender identity) who begin clinical gender affirming hormone therapy (GAHT) with testosterone (T) may experience changes in headache. Researchers think this because studies published on effects of giving testosterone to cisgender females (female sex, female gender identity) and transmasculine adults seem to show an effect on pain. This research will help us learn more about changes in headache and in brain structure and function in transmasculine youth during the first two years of T. Youth who will be starting T within 6 months, either on puberty blocker or not, as part of their regular medical care can participate and will be asked to attend 4 visits: * before starting T * after 6 months on T * after 1 year on T * after 2 years on T At the visits, they will be asked to: * answer questions and surveys about their health * have a brain MRI done * give a small sample of blood and at their first visit, complete a physical exam. Some participants can also do a brief test of pain sensitivity. All participants will be asked to complete a headache diary for the first 6 months, for 1 month after the 1 year visit, and for 1 month after the 2 year visit.
Primary Outcome
Change in number of headache days per month
Conditions Studied
Interventions
- DRUG Testosterone
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-31 |
| Est. Completion | 2026-12 |
What NCT06670053 shows while recruiting
NCT06670053 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 153-participant average among 35 other Headache trials with a reported enrollment target (35% lower).
The record links to 4 conditions, with Headache appearing as the primary indexed condition, and to 1 intervention - of which Testosterone is the first listed.
NCT06670053 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06670053 about?
NCT06670053 is a clinical study titled "Puberty, Testosterone, and Brain Development". Transmasculine youth (female sex assigned at birth, male gender identity) who begin clinical gender affirming hormone therapy (GAHT) with testosterone (T) may experience changes in headache. Researchers think this because studies published on effects of giving testosterone to cisgender females (fema...
What is the current status of trial NCT06670053?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-12-31. Estimated completion is 2026-12.
What conditions does trial NCT06670053 study?
This clinical trial studies the following conditions: Headache, Transgender, Gender Identity, Gender Dysphoria in Adolescents and Adults.
What interventions are being tested in trial NCT06670053?
The interventions under investigation include: Testosterone (DRUG).
Who is sponsoring clinical trial NCT06670053?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06670053 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Headache
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06670053's enrollment target sits among peer trials
100 16th of 35 higher than 20 of 35 other Headache trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Headache trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concussion Recovery and Support Program
RECRUITING · NA
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches
RECRUITING
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI